These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interleukin-6 as a key player in systemic inflammation and joint destruction. Fonseca JE; Santos MJ; Canhão H; Choy E Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867 [TBL] [Abstract][Full Text] [Related]
5. [IL-6 targeting therapy to retard structural joint damage in patients with rheumatoid arthritis]. Nishimoto N Clin Calcium; 2009 Mar; 19(3):425-31. PubMed ID: 19252253 [TBL] [Abstract][Full Text] [Related]
6. [A humanized anti-IL-6 receptor antibody(MRA) in RA therapy]. Hagihara K; Nishimoto N; Yoshizaki K Nihon Rinsho; 2002 Dec; 60(12):2401-7. PubMed ID: 12510369 [TBL] [Abstract][Full Text] [Related]
7. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases. Nakahara H; Nishimoto N Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials. Kavanaugh A Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740 [TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Park JY; Pillinger MH Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S4-10. PubMed ID: 17708744 [TBL] [Abstract][Full Text] [Related]
11. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Narazaki M; Tanaka T; Kishimoto T Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214 [TBL] [Abstract][Full Text] [Related]
12. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Nasonov EL Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275 [TBL] [Abstract][Full Text] [Related]